Exosomes in stroke pathogenesis and therapy

Zhenggang Zhang
Henry Ford Health System, zzhang1@hfhs.org

Michael Chopp
Henry Ford Health System, mchopp1@hfhs.org

Follow this and additional works at: https://scholarlycommons.henryford.com/neurology_articles

Recommended Citation

This Article is brought to you for free and open access by the Neurology at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Neurology Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.
Exosomes in stroke pathogenesis and therapy
Zheng Gang Zhang¹ and Michael Chopp¹,²

¹Department of Neurology, Henry Ford Hospital, Detroit, Michigan, USA. ²Department of Physics, Oakland University, Rochester, Michigan, USA.

Stroke is one of the leading causes of death and disability worldwide. Stroke recovery is orchestrated by a set of highly interactive processes that involve the neurovascular unit and neural stem cells. Emerging data suggest that exosomes play an important role in intercellular communication by transferring exosomal protein and RNA cargo between source and target cells in the brain. Here, we review these advances and their impact on promoting coupled brain remodeling processes after stroke. The use of exosomes for therapeutic applications in stroke is also highlighted.

Introduction
Stroke is one of leading causes of death and disability worldwide (1). Since it was approved by the FDA in 1996, tissue plasminogen activator (tPA) has become the only treatment for patients presenting with stroke within 4.5 hours of onset (2–5). Recently, endovascular thrombectomy has been shown to extend the therapeutic window for patients to within 12 hours after stroke onset by rapidly recanallizing the occluded blood vessels and reestablishing tissue perfusion, indicating that early tissue reperfusion can salvage dying brain cells (6–9). However, restoration of cerebral blood flow (CBF) beyond a critical time point cannot rescue irreversibly damaged brain cells, which leads to long-term disability in a large population of stroke survivors (9). High risk of brain hemorrhage also limits the tPA treatment to a small percentage of patients with ischemic stroke. Thus, there is a compelling need to develop therapies for early brain tissue perfusion after acute stroke and for enhancement of functional recovery in stroke survivors.

The neurovascular unit includes endothelial cells, vascular smooth muscle, glia, neurons, and associated tissue matrix proteins (9). Stroke induces highly dynamic alterations of the neurovascular unit, which contribute to the development of brain injury (9). During stroke recovery, ischemic brain undergoes limited remodeling, with a set of highly interactive processes involving components of the neurovascular unit and neural stem cells (10, 11).

Exosomes are endosome-derived small membrane vesicles, approximately 30 to 100 nm in diameter, and are released into extracellular fluids by cells in all living systems (12, 13). They are present in biofluids such as blood and the cerebrospinal fluid (CSF) (13). Exosomes carry proteins, lipids, and genetic materials and play essential roles in intercellular communication by transferring their cargo between source and target cells under physiological and pathophysiological conditions (12, 13). Emerging data indicate that exosomes regulate intercellular communication among components of the neurovascular unit after stroke. In this Review, we highlight recent insights into the role of exosomes and exosomal microRNAs (miRNAs) in brain repair processes after stroke and discuss potential applications of exosomes for stroke therapy.

Pathophysiology of ischemic stroke
Ischemic stroke is primarily caused by thromboembolic occlusion of a major artery that supplies the brain (9). When emboli or thrombi in situ occlude cerebral arteries, circulating platelets are rapidly recruited to the site of the occluded vessels (14). Platelets, along with thrombin and fibrin resulting from tissue factor-activated blood coagulation, are the primary contributors to thrombus development at the site of the occluded artery (14, 15). Concomitantly, occlusion of a major cerebral artery triggers development of secondary thrombosis in downstream microvessels, which causes dysfunction of cerebral endothelial cells, pericytes, and astrocytes and leads to disruption of the blood-brain barrier (BBB) and ischemic cell damage (16–19). The evolution of downstream microvascular thrombosis is heterogeneous and continues for hours and is highly associated with the progression of ischemic neuronal death from reversible to irreversible damage (14, 16–18). Thus, the primary goal for treatment of ischemic stroke is to rapidly recanallize the occluded blood vessels, reestablish CBF in the ischemic cerebral microvascular bed, preserve vascular integrity, and minimize neuronal death (18, 20).

During stroke recovery, ischemic brain undergoes a series of remodeling events that lead to limited spontaneous functional recovery (21). Relatively quiescent cerebral endothelial cells in preexisting blood vessels are activated, leading to angiogenesis in experimental stroke models and human ischemic brain (22–25). In addition to cerebral endothelial cells, circulating endothelial progenitor cells are also involved in the generation of new blood vessels (26). Stroke-induced angiogenesis not only occurs in the periinfarct regions, but also in the ventricular/subventricular zone (V/SVZ) of the lateral ventricles, a neurogenic region (27). At early stages of recovery, angiogenic vessels are permeable, but new vessels become less leaky and functional when they mature (23, 28). Increased angiogenesis is highly associated with improved neurological outcomes (10).

Neural stem cells are present in adult rodent brain in the V/SVZ and in the subgranular zone of the dentate gyrus (29). These neural stem cells generate new neurons throughout life (29). Stroke increases neurogenesis in experimental animals (30–33), and an increase in neural progenitor cells and neuroblasts has also been observed in human ischemic brain (34–38). Stroke-induced neurogenesis couples to angiogenesis (31, 39–43). In the

Conflict of interest: The authors have declared that no conflict of interest exists.
and oligodendrogenesis during repair after stroke (52). Recent studies indicate that cerebral endothelial cells actively and continuously generate oligodendrocyte progenitor cells (OPCs) that differentiate into myelinating oligodendrocytes (45–47). Mature oligodendrocytes are terminally differentiated and are vulnerable to cerebral ischemia. During brain repair processes, new oligodendrocytes generated by OPCs form myelin sheaths around the regenerated axons in periinfarct gray and white matter (48–51). Studies indicate that cerebral endothelial cells actively and mutually interact with oligodendrocytes to facilitate angiogenesis and oligodendrogenesis during repair after stroke (52).

**Exosomes and miRNAs**

Experimental studies have provided new insight into cellular and molecular mechanisms that underlie the intertwined brain remodeling processes. Both intracellular and intercellular molecules mediate the intertwined brain remodeling events via autocrine and paracrine signaling effects. For example, downregulation of miRNA-15a (miR-15a) in cerebral vessels in a mouse model of focal cerebral ischemia promotes stroke-induced angiogenesis in the perifuct region by increasing FGF2 and VEGF levels (53). VEGF released by angiogenic endothelial cells also interacts with its receptor VEGFR2 in neural progenitor cells to promote their proliferation and neuronal differentiation (54). Moreover, cerebral endothelial cells in white matter are involved in regeneration of myelinating oligodendrocytes through brain-derived neurotrophic factor (BDNF) and FGF2 in injured brain (52). Stroke-induced limited axonal sprouting and remyelination in the perifuct region are also regulated by miRNAs. In vitro and in vivo studies showed that stroke-induced downregulation of miR-9 and miR-200b expression in white matter mediates remyelination (55). Chondroitin sulfate proteoglycans (CSPGs) produced by reactive astrocytes inhibit axonal regrowth (56). Overexpression of the miR-17–92 cluster or miR-27a in cultured cortical neurons activates neuronal intrinsic growth signals by suppressing phosphatase and tensin homolog (PTEN) and ras homolog family member A (RhoA) signals, thereby overcoming the CSPG inhibitory effect (57, 58). In vivo studies of spinal cord injury in adult animals have shown that suppression of the PTEN signaling pathway within neurons enhances axonal sprouting even in the presence of CSPGs (57, 59). Thus, the miRNA and mRNA networks play a pivotal role in mediating brain-repair processes (60).

Emerging data suggest that exosome-mediated intercellular communication contributes to brain remodeling by transferring cargo from source cells to target cells (ref. 12 and Figure 1). Exosomes can be isolated from biofluids such as CSF and from the supernatant of cells cultured in exosome-free medium by centrifugation and other methods (61). Exosomes are generally enriched with tetraspanin proteins (CD63, CD81), the regulator of endosomal trafficking Alix, and the chaperone protein HSP70, although the content of exosomes varies with cell origin and physiological and pathological conditions (13, 61). Tetraspanins, Alix, and HSP70 have been used as exosomal markers (13). Proteomic and RNA analyses have demonstrated that exosomes carry cargoes of lipids, proteins, and RNAs, including miRNAs and mRNAs (13, 61); however, it is unclear how biological materials are loaded into individual exosomes.

All brain cells release exosomes (61). In vivo studies show that rodent and human brains release exosomes (62, 63). Compared with exosomes isolated from wild-type mouse brain, exosomes from brains of transgenic mice overexpressing human amyloid-β (Aβ) precursor protein (APP) contain high levels of full-length APP and C-terminal fragments of APP (62). Full-length and C-terminal fragments of APP were also detected within exosomes from brain tissue of an Alzheimer’s disease (AD) patient (62). Full-length APP cleavage by β-secretase occurs within endosomes, a fraction of Aβ peptides is sorted to multivesicular bodies, and these Aβ peptides are released in association with exosomes (64). In addition, exosomes isolated from prefrontal cortices of patients with schizophrenia and bipolar disorder showed different profiles of exosomal miRNAs compared with exosomes from brains of control subjects (63). Collectively, these studies suggest that exosomes released by both human and mouse brains under disease conditions change profiles of exosomal cargo proteins and miRNAs and that exosomes enriched with neurotoxic C-terminal fragments of APP may contribute to the spread of Aβ peptides to the brain. Although these in vivo studies are not able to indentify cellular sources of these exosomes, data from cultured cells suggest that exosomes released by neurons and astrocytes contain Aβ peptides (see details below) (64, 65). It will be interesting to examine changes of brain exosomal cargo profiles and to investigate the role of their cargo in brain repair processes after stroke.

**Exosomes and cerebral angiogenesis**

In vitro and in vivo experiments have shown that exosomes from circulating endothelial progenitor cells transfer cargo mRNAs associated with the PI3K/Akt signaling pathway and proangiogenic miRNAs, such as miR-126 and miR-296, into recipient endothelial cells (66, 67). Within the recipient endothelial cells, these miRNAs activate the PI3K/Akt signaling pathway, leading to angiogenesis (66, 67). In the brain, exosomes from cultured glioblastoma cells induce angiogenesis by delivering their contents of proangiogenic proteins, mRNAs, and miRNAs into cerebral endothelial cells (68). Additionally, immortalized human brain microvascular endothelial cells secrete exosomes (69). Proteomic analysis has demonstrated that exosomes released by human cerebral endothelial cells contain 1,179 proteins, including several receptors that carry macromolecules across the BBB, such as transferrin receptor and insulin receptor (69). The role of these exosomal proteins has not been investigated, but interactions between cerebral endothelial exosomes and pericytes have been studied (70). Exosomes secreted by immortalized mouse cerebral endothelial cells stimulated by LPS and cytokines transferred cargo miRNAs and increased VEGF-B mRNA and protein levels in recipient cerebral vascular pericytes (70). VEGF-B and its receptor VEGFR-1 mediate angiogenesis (71).
Exosomes and neurogenesis

Neural stem cells in the V/SVZ of the adult rodent brain exist in a unique niche where they contact blood vessels, neighboring cells, and CSF, constantly exchanging molecular signals (79). We are just beginning to understand how intercellular molecular signals interact among the individual components within the niche. There is evidence that exosomes in CSF and neural stem cells mediate neural stem cell function and immune system function, respectively, by regulating intercellular pathways (80, 81). Exosomes isolated from embryonic CSF of rats and humans contain protein and miRNA components of the IGF signaling pathway (80). CSF-exosome cargoes, including both proteins and miRNAs, are highly conserved between rodent and human (80). Incubation of embryonic neural stem cells with CSF exosomes activated the IGF/mTORC1 pathway in the neural stem cells and promoted stem cell proliferation (80). Exposure of neural stem cells derived from V/SVZ neural stem cells of adult mouse to proinflammatory cytokines led to release of exosomes enriched with miRNAs encoding components of the IFN-γ signaling pathway (81). These exosomes activated STAT1 signaling in recipient cells through exosome-associated IFN-γ and its receptor IFNGR1 (81). Stroke activates innate and adaptive immune responses (82); thus, exosomes released by neural stem cells may also communicate with the immune system after stroke.

Exosomes and neuronal plasticity

Neurons and glia actively communicate with each other to coordinate axonal growth and myelination, and emerging data suggest that exosomes released by neurons and glia contribute to these processes (61, 83, 84). Exosomes released by cultured cortical neurons carried the neuronal-specific protein L1 cell adhesion molecule (L1CAM) and the GluR2/3 subunits, but not the NR1 subunits, of glutamate receptors (85, 86). Increasing cytosolic calcium in neurons and neuronal depolarization augmented the secretion of exosomes (85–87). Notably, exosomes released by neurons contain alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors, while exosomes secreted from neurites of depolarized neurons are enriched with microtubule-associated protein 1b (MAP1b) and miRNAs that target genes involved in neurite plasticity (86, 87). Exosomes from neurons treated with a retinoic acid receptor β2 (RARβ) agonist had a dual effect on neurons and astrocytes to inactivate PTEN signaling, leading to enhancement of neurite outgrowth (88). RARβ agonist inactivated cortical neuron PTEN signaling by releasing exosomes enriched with PTEN. These PTEN-enriched neuronal exosomes transferred PTEN proteins into astrocytes to suppress astrocyte proliferation (88). In addition to neurons, exosomes released by cortical neurons transferred miR-124 to astrocytes and increased the expression of the excitatory amino acid transporter GLT-1 in astrocytes, suggesting a role for neuronal exosomes in regulat-
ing astrocyte function (89). AMPA receptors and MAP1b are key regulators of synaptic and dendritic plasticity and axonal spouting (86, 87, 90). The astrocyte glutamate transporter GLT-1 in rodent regulates extracellular glutamate levels and modulates synaptic activation (89). Activation of AMPA receptors contributes to motor function recovery after stroke (91). Suppression of neuronal PTEN signals and reduction of an astrocyte scar promote axonal sprouting in adult CNS after spinal cord injury and stroke (57, 59, 92). Together, these data suggest that neuronal exosomes mediate synaptic and axonal plasticity by synaptic transfer of their cargo (93). Together, these data suggest that neuronal exosomes mediate synaptic and axonal plasticity by synaptic transfer of their cargo to neurons and by communication with astrocytes (86, 93), which potentially mediate axonal and synaptic remodeling in the ischemic brain.

Exosomes and glia
Exosomes derived from embryonic chicken astrocytes contain HSP70 (94). Treatment of astrocytes from newborn mice with high KCl concentrations led to release of exosomes enriched with synapsin, a synaptic vesicle–associated protein that enhances neurite growth and neuronal survival (95). A range of KCl concentrations can induce astrocyte secretion of exosomes in the ischemic brain (95, 96). Thus, such processes may occur in activated astrocytes after stroke.

Cultured oligodendrocytes secrete exosomes, and cytosolic calcium levels in oligodendrocytes regulate exosomal secretion (97). Proteomic analysis showed that oligodendrocyte-derived exosomes contained major myelin proteins, proteolipid protein (PLP), 2′3′-cyclic-nucleotide-phosphodiesterase (CNP), and myelin basic protein (MBP) (97). Glutamate from activated neurons also stimulates oligodendrocytes to release exosomes that carry MBP, PLP and sirtuin-2 (SIRT2) (98). These proteins inhibit myelination by activating Rho/ROCK/myosin signaling in recipient target cells (99). Transmission electron microscopic analysis showed the presence of PLP+ multivesicular bodies in the perixonal space (61), indicating that exosomes contribute to neuronal-mediated coordination of myelination (61). In addition to myelination, exosomes from oligodendrocytes can be internalized by neurons and thereby improve neuronal viability under conditions of cell stress (98). In a model of in vitro ischemia, treatment of cortical neurons subjected to oxygen/glucose deprivation with oligodendrocyte-derived exosomes reduced ischemic neuronal death, which resulted from activation of signaling pathways in neurons by exosome cargo of superoxide dismutase, catalase, and other antioxidant enzymes (100). Thus, it appears that oligodendrocyte exosomes have multifaceted effects on neurons.

Microglia are a heterogeneous population of cells in the CNS and play a primary role in immune responses. Cultured primary microglia and microglia from a cell line released exosomes that contained the aminopeptidase CD13 and the lactate transporter monocarboxylate transporter 1 (MCT-1) (101). Microglial exosomes transferred CD13 to neurons, evoking neuropeptide degradation (101). Microglia can also take up exosomes secreted by other brain cells. In vitro and in vivo studies have demonstrated that exosomes from OPCs were preferentially internalized by microglia via a macrophagocytic mechanism (102). Compared with naïve microglia, microglia challenged by IFN-γ substantially reduced uptake of OPC exosomes (102). Microglia are also involved in the modulation of synaptic pruning, neurogenesis, and oligodendrogenesis (103–105). For example, SVZ-resident microglia mediate neuroblast migration, whereas in the hippocampus, IL-4– and IFN-γ–activated microglia promote oligodendrogenesis and neurogenesis, respectively (104, 105). These data imply that microglial exosomes regulate oligodendrogenesis and neurogenesis under physiological and pathological conditions.

Exosomes and cognitive deficits
Stroke accelerates development of cognitive decline and AD, which are characterized by the presence of Aβ in the brain (18). Aβ is secreted into the extracellular milieu, and an imbalance between production and clearance leads to accumulation of Aβ (106). Exosomes secreted by cultured N2a neuroblastoma cells contained Aβ (64). Internalization of neuronal exosomes by microglia enhanced microglial capability to take up and degrade Aβ (107). In addition, statins, including simvastatin, stimulated microglia to secrete exosomes that were enriched with insulin-degrading enzyme (IDE), which is known to degrade Aβ (108). These IDE-enriched exosomes promoted clearance of extracellular Aβ peptides (108). These studies suggest that microglia clear Aβ peptides by either internalization of exosomes derived from other cells or secretion of their own exosomes after statin treatment. Treatment of stroke and traumatic brain injury (TBI) with simvastatin enhanced ischemic brain repair processes, including axonal sprouting, and improved spontaneous object recognition and temporal order memory (109, 110). However, whether the statin treatment alters the ability of microglial exosomes to degrade Aβ peptides in the injured brain remains to be investigated.

Exosomes derived from pathological cells are involved in the progression of neurological disorders. Exosomes derived from astrocytes of mice overexpressing mutant copper-zinc SOD1, a model of familial ALS, or astrocytes treated with Aβ peptides have been shown to induce motor neuron death and astrocyte apoptosis, respectively, by shuffling mutant SOD1 and proapoptotic proteins into the recipient cells (111, 112).

MSC-derived exosomes and therapies
Cell therapies including bone mesenchymal stem cells (MSCs) improve neurological outcome after stroke and TBI (10, 18), and MSC therapy is in clinical trials for stroke (Table 1). Preclinical studies have demonstrated that MSCs promote angiogenesis, neurogenesis, and white matter remodeling in the injured brain by secreting factors to trigger the signaling pathways that are involved in brain repair. These findings indicate that paracrine effects of administered MSCs on brain parenchymal cells, but not cell replacement, underlie the benefits of MSC therapy (10, 18).

Compared with other cell types, cultured MSCs secrete a large quantity of exosomes (113). Emerging data from independent laboratories indicate that exosomes released from MSCs provide therapeutic benefits in stroke and TBI by modulating the brain microenvironment (114–119). Intravenous administration of MSC-derived exosomes to rats subjected to focal cerebral ischemia or TBI substantially improved neurological function by promoting neurovascular remodeling during stroke and TBI recovery (116, 117, 119). Subsequently, the therapeutic
The therapeutic effect of MSC-derived exosomes has also been demonstrated by independent laboratories in the mouse subjected to stroke and TBI (114, 115). Systemic administration of MSC-derived extracellular vesicles to ischemic mice markedly reduced motor coordination deficits and enhanced angiogenesis and neurogenesis, while treatment of TBI mice with human MSC-derived extracellular vesicles substantially preserved spatial leaning ability (114, 115). Improved neurological outcomes from these MSC-derived exosome studies are comparable to the therapeutic effect observed with MSC therapy, suggesting that MSC-derived exosome-mediated cell-cell communication may contribute to the therapeutic effect of the MSC therapy.

Exosomes transfer their cargo miRNAs to recipient cells (120, 121) and MSC-derived exosomes contain more than 700 miRNAs that are bound to argonaute2 (AGO2), a component of the RNA-induced silencing complex (RISC) (122, 123). The effect of engineered MSC-derived exosomes that carry elevated miRNAs on brain remodeling after stroke has been investigated in vitro and in vivo (118, 119). Treatment of stroke models with MSCs abolished stroke-induced downregulation of miR-133b in the ischemic brain (118). When MSCs were cultured with extracts harvested from ischemic brain tissues, they released exosomes enriched with miR-133b. Tailored MSC-derived exosomes with elevated or reduced miR-133b were harvested from the supernatant of MSCs transfected with lentiviral vectors carrying pre-miR-133b or anti-miR-133b, respectively (118, 119). Intravenous administration of tailored MSC-derived exosomes with increased or decreased miR-133b to rats with stroke led to enhancement or exacerbation, respectively, of axonal remodeling and neurological function compared with naturally occurring MSC-derived exosomes (119). Connective tissue growth factor (CTGF) and RhoA are putative targets of miR-133b and are known to suppress neurite growth (118). In vitro, incubation of cortical neurons with miR-133b–elevated exosomes downregulated RhoA and enhanced neurite outgrowth, whereas treatment of astrocytes with miR-133b–elevated exosomes suppressed CTGF, which is mainly expressed by astrocytes (119, 124). Collectively, these data indicate that MSC-derived exosomes may be used as vehicles to transport miRNAs that modulate genes in the recipient neurons and astrocytes.

Stroke induces immunosuppression in the peripheral blood, which exacerbates stroke outcome (125–127). In addition to interactions with brain cells, MSC-derived exosomes administered to ischemic mice appear to communicate with natural killer cells and lymphocytes in the peripheral blood to attenuate postischemic immunosuppression (114).

HSC-exosomes and therapies

Studies from myocardial ischemia have shown that engineered exosomes with elevated sonic hedgehog (Shh) derived from CD34+ hematopoietic stem cells (HSCs) transferred functional Shh and activated the Shh signaling pathway in recipient cells, enhancing angiogenesis in the border zone of infarction and preserving cardiac function (128). Shh (129–131) plays an important role in the regulation of adult neurogenesis under physiological and pathological conditions (132–135). These experiments suggest that exosomes can deliver functional proteins to modulate cellular function of recipient cells and that treatment of stroke with tailored Shh-exosomes could facilitate brain remodeling.

Exosomes can cross the BBB (13, 136). For example, intranasal administration of Odyssey 800 dye–labeled exosomes derived from a glioblastoma cell line led to distribution of fluorescent particles throughout the brain, mainly in the olfactory bulb in mice (136). Using the Cre-loxP system, studies have demonstrated that intrahippocampal injection of Cre-recombinase mRNA containing exosomes into mice with a ROSA26-lacZ reporter activated a lacZ reporter in the hippocampal neurons (98), indicating that Cre-recombinase mRNA within the exosomes activates the reporter gene in recipient neurons. Furthermore, intravenous injection of exosomes expressing a fusion protein consisting of the neuron-specific rabies virus glycoprotein (RVG) peptide with the exosomal membrane protein LAMP2B demonstrated targeting of neurons, microglia, and oligodendrocytes in the brain (137). Intravenous administration of the RVG peptide–expressing exosomes carrying siRNA against opioid receptor mu (MOR) enhanced the movement of exosomes across the BBB and inhibited MOR expression in the brain (138). These data suggest that exosomes not only cross the BBB, but also deliver functional cargo to trigger gene expression in specific recipient cell types in the brain.
Perspectives

Exosomes are emerging as important intercellular players in mediating neurorestorative events after stroke and neural injury (139–141). Preliminary work demonstrates that either naturally occurring or engineered exosomes derived from stem/progenitor cells provide therapeutic benefits (139–141). However, there are multiple unanswered questions and challenges in the development of exosome therapy including the following: (a) identification of the cellular signals by which the ischemic brain is able to affect the content and quantity of exosomes released by brain parenchymal cells and by remote organs, (b) understanding how exosomal cargo affects expression of endogenous genes and proteins in recipient cells of injured brain, (c) delineation of the specific cell types that are targeted by brain parenchymal cell-derived exosomes, and (d) knowledge of the effects of sex, age, and comorbidity on the cellular generation of exosomes and their cargo and the effect of sex, age and comorbidity in response to exosome treatment after stroke. Ongoing studies to investigate exosomes as a means of intercellular communication in ischemic brain will provide novel insights into the role of exosomes in the development of stroke pathogenesis and aid in the development of exosomal therapies to enhance stroke recovery.

Acknowledgments

The authors are supported by the following NIH grants: R01 NS 088656 (to M. Chopp), R01 NS075156 (to Z.G. Zhang), and R01 NS079612 (to Z.G. Zhang). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Address correspondence to: Zheng Gang Zhang, Department of Neurology, 2799 West Grand Blvd., Detroit, Michigan 48202, USA. Phone: 313.916.5456; E-mail: zhazh@neuro.hfh.edu.


